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,
Morbidity and Mortality Caused by Cardiac
Adverse Events after Revascularization
for Critical Limb IschemiaH.C. Flu,1 J.H.P. Lardenoye,2 E.J. Veen,1 A.E. Aquarius,3 D.P. Van Berge Henegouwen,1
and J.F. Hamming,2 Tilburg, The NetherlandsBackground: We assessed cardiac adverse events (AEs) after primary lower extremity arterial
revascularization (LEAR) for critical lower limb ischemia (CLI) in order to evaluate the impact of
cardiac AEs on the clinical outcome. We created an optimized care protocol concerning CLI
patients’ preoperative work-up as well as intra- and postoperative surveillance according to
recent important literature and guidelines.
Methods: We conducted a prospective analysis of clinical outcome after LEAR using patient-
related risk factors, comorbidity, surgical therapy, and AEs. This cohort was divided into patients
with and without AEs. AEs were categorized according to predefined standards: minor, surgical,
failed revascularization, and systemic. The consequences of AEs were reoperation, additional
medication, irreversible physical damage, and early death.
Results: There were 106 patients (Fontaine III n¼ 49, 46%, and Fontaine IV n¼ 57, 56%) who
underwent primary revascularization by bypass graft procedure (n¼ 67, 63%) or balloon angio-
plasty (n¼ 39, 37%). No difference in comorbidity was registered between the two groups.
Eighty-four AEs were registered in 34 patients (32%). Patients experiencing AEs had signifi-
cantly less antiplatelet agents (without AEs n¼ 63, 88%, vs. with AEs n¼ 18, 53%; p¼ 0.000)
and/or b-blockers (without AEs n¼ 66, 92%, vs. with AEs n¼ 16, 47%; p¼ 0.000) compared
to patients without AEs. The two most harmful consequences of AEs were irreversible physical
damage (n¼ 3) and early death (n¼ 8). Sixty percent (n¼ 9) of systemic AEs were heart-related.
The postprocedural mortality rate was 7.5%, with a 75% (n¼ 6) heart-related cause of death.
Conclusion: AEs occur in >30% of CLI patients after LEAR. The most harmful AEs on the
clinical outcome of CLI patients were heart-related, causing increased morbidity and death.
Significant correlations between prescription of b-blockers and antiplatelet agents and prevention
of AEs were observed. A persistent focus on the prevention of systemic AEs in order to amelio-
rate the outcome after LEAR for limb salvage remains of utmost importance. Therefore, we
advise the implementation of an optimized care protocol by discussing patients in a strict manner
according to a predetermined protocol, to optimize and standardize the preoperative work-up as
well as intra- and postoperative patient surveillance.nt of Vascular Surgery, St. Elisabeth Hospital, Tilburg,
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Lower extremity peripheral arterial obstructive
disease (PAOD) is a common syndrome that affects
a large part of most adult populations in the Western
world;1-7 it affects about 5% of the population aged
between 55 and 74 years.8,9 The clinical manifesta-
tions of PAOD are a major cause of acute and
chronic illness. In addition, PAOD is associated
with decrements in functional capacity, decreased
quality of life, and increased risk of death.
Patients undergoing primary lower extremity
arterial revascularization (LEAR), for critical limb
ischemia (CLI) represent a dynamic challenge for583
584 Flu et al. Annals of Vascular Surgerythe anesthetist and the surgeon that extends beyond
the intricacies of the planned operation. These
patients frequently have arterial disease affecting
several vascular beds and suffer from other signifi-
cant comorbidities such as diabetes, respiratory
disease, and renal disease. Also, CLI patients have
an even greater risk of experiencing cardiovascular
ischemic events.10-13 Undergoing LEAR, they are
at increased risk of life-threatening peri- and postop-
erative cardiac adverse events (AEs), such as
myocardial infarction.14-16 Fifty percent of patients
operated for CLI die within 5 years,11,17,18 mainly
due to cardiovascular events.19-21
In order to improve the postoperative outcome of
patients undergoing primary LEAR, the pre-, intra-,
and postoperative hemodynamic optimization,
cardiac management, and timely detection of post-
operative AEs could be one of the main goals during
endovascular or surgical definitive treatment of
these high-risk CLI patients.
Prospective evaluation of AEs is helpful and
necessary to obtain a good insight into the occur-
rence of AEs after treatment for CLI in vascular
surgery; it can be used as an indicator of quality in
surgery and care.22-29 It is important to gain insight
into the causes and consequences of AEs in patients
after LEAR for CLI. Therefore, the objectives of the
present study were (1) to assess the occurrence of
AEs after LEAR for CLI and (2) to examine the
impact of AEs on the clinical outcome of CLI
patients’ general health.MATERIALS AND METHODSPatientsA 2-year survey was performed on 106 consecutive
patients without a history of LEAR or amputations.
They were admitted for the first time with CLI and
underwent primary LEAR. Criteria for inclusion in
the study population was CLI, ischemic rest pain
(Fontaine stage III) with a resting ankle pressure
of <50 mm HG, and gangrene or nonhealing
ischemic ulceration (Fontaine stage IV) with a
resting ankle pressure of <70 mm HG. This corre-
sponds with categories 4, 5, and 6 of the Society of
Vascular Surgery/North American Chapter of the
International Society for Cardiovascular Surgery
(SVS/ISCVS) standards30,31 and the Trans-Atlantic
Inter-Society Consensus (TASC) Document on
Management of Peripheral Arterial Disease.1,2 The
included femoral popliteal lesions were according
to TASC type B, C, or D for plaque morphology.1,2
The cohort was divided into patients with AEs and
without AEs during admission.Risk Factors and ComorbidityRisk factors and comorbidities were registered
prospectively for all patients during their admission
intake. Smoking, hypertension, cardiac disease,
hyperlipidemia, diabetes mellitus, renal disease,
pulmonary disease, carotid disease, and age were
classified according to the SVS/ISCVS and TASC
reporting standards. The risk factor and comorbidity
management, according to TASC and American
Heart Association/American College of Cardiology
(AHA/ACC) reporting standards, was conducted by
either a vascular specialist or a cardiologist preopera-
tively in the outpatient clinic or during admission
before operation when urgent intervention was indi-
cated. Also the body mass index (BMI)32 of the
patients was determined, divided into normal
(18.5-24.9 kg/m2), overweight (25.0-29.9 kg/m2),
and adipose (>30 kg/m2). Data on risk factors and
comorbidities are listed in Table I.MedicationMedication use according to the TASC and AHA/
ACC reporting standards was listed by the patients
at baseline; secondary prevention prescribed drugs,
recorded at admission for purposes of analysis,
were reviewed and classified according to the
following categories: antiplatelet agents, b-blockers,
and HMG-CoA reductase inhibitors.RevascularizationThe vascular treatment (LEAR) consisted of percuta-
neous transluminal angioplasties (PTAs) and bypass
graft procedures. The PTAs were carried out by
conventional balloon dilatation of the lesion with
or without stent placement and under regional anes-
thesia. Patients were prescribed with a daily dose of
acetylsalicylic acid/aspirin after the PTA was per-
formed. The bypass graft procedure (BGP) was per-
formed according to standard vascular techniques,
using preferably reversed vein for femoral popliteal
(supra- and infragenual) and crural BGPs and under
general anesthesia. Patients were prescribed a daily
dose of coumarin after the BGP was performed.
The patency of a BGP was determined by duplex
ultrasound examination and ankle-brachial indices
in all patients 4 weeks after LEAR. The definition of
primary and secondary patency, the decision to
intervene, and the type of intervention were driven
by the SVS/ISCVS and TASC reporting standards.
The nonvascular treatment consisted of drainage/
debridement, a minor amputation (defined as toe
or foot amputation), and a major amputation
(defined as an amputation above or below the level
Table I. Baseline characteristics of the total sample (n¼ 106) stratified by patients with and without AEs
Characteristics Total Without AE With AE p
Gender 0.987a
Male 56 (53) 38 (53) 18 (53)
Female 50 (47) 34 (47) 16 (47)
Age (years) 0.412a
<55 14 (13) 9 (13) 5 (15)
55e69 30 (28) 23 (32) 7 (20)
70e79 43 (41) 25 (35) 18 (53)
>80 19 (18) 15 (21) 4 (12)
BMI32 0.788a
Normal 60 (57) 41 (57) 19 (56)
Overweight 40 (38) 26 (36) 14 (41)
Adiposity 6 (6) 5 (7) 1 (3)
Comorbidity
Cardiac disease 52 (49) 32 (44) 20 (59) 0.167a
Pulmonary disease 33 (31) 21 (29) 12 (35) 0.525a
Renal disease 33 (31) 23 (32) 10 (29) 0.793a
Diabetes mellitus 44 (42) 23 (32) 11 (32) 0.426a
Hypertension 60 (57) 40 (56) 20 (59) 0.751a
Tobacco use 65 (61) 44 (61) 21 (62) 0.129a
Hyperlipidemia 46 (43) 34 (47) 12 (35) 0.247a
Carotid disease 24 (23) 13 (18) 11 (32) 0.101a
SVS-ISCVS risk
score30,31
Mean (SD) 0.78 (0.59) 0.74 (0.62) 0.87 (0.52) 0.299a
(minemax) (0e2.3) (0e2.3) (0e2.1)
Risk factors
Median (SD) 3.0 (1.9) 3.0 (1.9) 3.5 (1.8) 0.270b
(minemax) (1e8) (1e8) (1e8)
Secondary prevention
Antiplatelet agent 81 (76) 63 (88) 18 (53) 0.000a
ß-blocker 82 (77) 66 (92) 16 (47) 0.000a
HMG-CoA reductase
inhibitor
91 (86) 61 (85) 30 (88) 0.628a
Data are presented as n and percentages, unless otherwise specified. SD, standard deviation.
aChi-squared test.
bMann-Whitney U-test.
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under the supervision of a vascular surgeon.Adverse EventsIn The Netherlands, the Association of Surgeons of
the Netherlands (ASN) has agreed on one common
definition of AEs.33-37 This definition differs from
that used in other studies because it has been chosen
with the explicit aim of excluding subjective judg-
ment on cause and effect, as well as right and wrong.
The definition of an AE is ‘‘an unintended and
unwanted event or state occurring during or
following medical care, that is so harmful to
a patient’s health that (adjustment of) treatment is
required or that permanent damage results. The AE
may be noted during hospitalization, until 30 daysafter discharge or transfer to another department.
The intended result of treatment, the likelihood of
the adverse outcome occurring, and the presence
or absence of a medical error causing it, is irrelevant
in identifying an adverse outcome.’’37 This defini-
tion did not change during the study period.
In 1993 a fully automated registration system
(self-developed Microsoft Access application with
an Oracle database as back-end) was implemented
in the surgical department of the St. Elisabeth
Hospital in Tilburg, The Netherlands. In 1995 total
coverage was reached, and registration of AEs was
also possible in the intensive care unit, operating
room, emergency department, and outpatient clinic.
Since 1995 the system has been based on an elabo-
rated list of criteria developed by the ASN (Appen-
dices I and II). AEs are registered immediately by
Fig. 1. Patients divided by the most
important AEs that occurred during the
postoperative period resulting in their
consequences. All data are presented as
percentages, unless otherwise specified.
Group 1, minor; group 2, surgical;
group 3, failed revascularization; group
4, systemic; I, no consequences; II,
additional transfusion/medication; III,
reoperation; IV, irreversible physical
damage; V, death.
586 Flu et al. Annals of Vascular Surgerythe physician who diagnoses them. The registered
AEs are evaluated and discussed during a weekly
meeting with all senior surgeons, surgical residents,
and interns. As shown in Figure 1 and Appendix I,
patients with AEs were subdivided into four groups:
minor, surgical, failed revascularization, and
systemic.Registration and Statistical AnalysisPatient information was registered prospectively in
an electronic patient file (Oracle database) used for
all patients during their admission intake. The
review was retrospective, and this material was
entered in a specifically designed computerized anal-
ysis database for vascular patients, developed in
Access (Office XP from Microsoft, Redmond, WA).
Statistical analyses were performed through a
computerized software package, using Excel (Office
XP from Microsoft) and SPSS 16.0 for Windows
(SPSS, Inc., Chicago, IL). Following completion of
the data collection, univariate analyses were per-
formed using chi-squared and unpaired Student’s
t-test. The secondary procedures and AEs were
analyzed with the Mann-Whitney U-test. Univariate
and multivariate analyses were performed using AEs
(minor, surgical, systemic, and failed revasculariza-
tion) as dependent variables, adjusting for gender,
age, BMI, cardiac disease, pulmonary disease, renal
disease, diabetes mellitus, hypertension, tobacco
use, hyperlipidemia, carotid disease, SVS-ISVCS
risk score, antiplatelet agents, b-blockers, and HMG-
CoA reductase inhibitors. For all statistical analyses,
p< 0.05 was considered statistically significant. The
life-table analysis, constructed as described by SVS-
ISCVS standards, was used to investigate differences
in primary patency, secondary patency, limb
salvage, and survival rates.RESULTSPatients, Risk Factors, and ComorbidityA total of 56 men (53%) and 50 women (47%)
underwent LEAR because of CLI. Mean ages were
72 and 70 years, respectively (range 47-93). Indica-
tion for LEAR was Fontaine III in 49 patients (44%)
and Fontaine IV in 57 patients (56%). Mean dura-
tion of admission was 9 and 13 days, respectively
(range 2-82). These patients suffered from cardiac
disease (n¼ 52, 49%), pulmonary disease (n¼ 33,
31%), renal disease (n¼ 33, 31%), diabetes mellitus
(n¼ 39, 38%), and hypertension (n¼ 60, 57%),
resulting in a mean patient risk score of 0.8. In the
patient group, 46 patients (43%) were overweight
or obese. A summary of the risk factors and disease
characteristics is listed in Table I; no significant
differences in risk factors were found between
patients with and those without AEs.MedicationUnivariate analysis. Concerning secondary preven-
tion, a difference was present concerning prescrip-
tion drugs: antiplatelet agents (total n¼ 81, 76%;
without AEs n¼ 63, 88%, vs. with AEs n¼ 18,
53%; p< 0.000) and b-blockers (total n¼ 82,
77%; without AEs n¼ 66, 92%, vs. with AEs
n¼ 16, 47%; p< 0.000). No difference was present
concerning HMG-CoA reductase inhibitors (total
n¼ 91, 86%; without AEs n¼ 61, 85%, vs. with
AEs n¼ 30, 88%; p¼ 0.628). Concerning secondary
prevention, 75-86% of CLI patients were on
target with the TASC and AHA/ACC reporting
guidelines.
Multivariate analysis. Not prescribing b-blockers
and antiplatelet agents was associated with the
occurrence of AEs (odds ratio [OR]¼ 0.017,
Vol. 23, No. 5, September 2009 Cardiac adverse events and critical limb ischemia 587p¼ 0.000, and OR¼ 19.808, p¼ 0.000, respec-
tively). Subsequently, not prescribing b-blockers
was associated with the occurrence of the subcate-
gory of systemic AEs (OR¼ 0.00, p¼ 0.000).RevascularizationPrimary procedures. Concerning the TASC type of
femoral popliteal lesion stratified by patients with
and those without AEs, no difference was seen
(TASC B, without AEs n¼ 26, 36%, vs. with AEs
n¼ 13, 38%; TASC C, without AEs n¼ 12, 17%,
vs. with AEs n¼ 4, 12%; TASC D, without AEs
n¼ 34, 47%, vs. with AEs n¼ 17, 50%; p¼ 0.805).
Concerning the PTAs stratified by patients with or
without AEs, no difference was seen (total n¼ 39,
37%; without AEs n¼ 26, 36%, vs. with AEs
n¼ 13, 38%; p¼ 0.345). There was a total of 67
primary BGPs (63%): reversed vein in 57 (85%)
and polytetrafluoroethylene (PTFE) in 10 (15%).
Concerning the type of BGP stratified by patients
with or without AEs, no difference was seen
(femoral popliteal supragenual total n¼ 16, 15%,
and without AEs n¼ 12, 17%, vs. with AEs n¼ 4,
12%; femoral popliteal infragenual total n¼ 30,
28%, and without AEs n¼ 20, 28%, vs. with AEs
n¼ 10, 29%; femoral crural total n¼ 21, 20%, and
without AEs n¼ 14, 19%, vs. with AEs n¼ 7,
21%; p¼ 0.822).
Secondary procedures. Secondary procedures
occurred only in patients with AEs (total n¼ 23,
40%, p¼ 0.000; vascular n¼ 8, 35%, p¼ 0.000;
nonvascular n¼ 15, 65%, p¼ 0.000). As listed in
Table II, no difference ( p¼ 0.817) was seen in
primary LEAR (PTA p¼ 0.345, BGP p¼ 0.822) in
all patients stratified by the occurrence of AEs. The
total 30-day cumulative life-table primary and
secondary patency rates of all BGPs and limb salvage
rates were 89%, 97%, and 99%, respectively.Adverse EventsThirty-four patients (men n¼ 18, 53%, and women
n¼ 16, 47%) experienced AEs. Sixty-five percent of
the patients were 70 years or older. Indication for
LEAR was Fontaine III in 13 (38%) and Fontaine
IV in 21 (62%) patients.
As listed in Tables III and IV, a total of 48 AEs
(during admission n¼ 43, 90%, and postdischarge
in the outpatient clinic n¼ 5, 10%) were registered:
50% were categorized as minor/surgical and 50% as
failed revascularization/systemic AEs, resulting in
secondary procedures as listed in Table IV. In
Figure 1, the AEs are related to their short-term
outcomes. Minor AEs resulted equally in no conse-
quence or in additional transfusion/medication.Surgical AEs resulted almost equally in additional
transfusion/medication (56%) and in reoperation
(44%) because of postoperative hemorrhage
(n¼ 2) or wound drainage (n¼ 2). Patients catego-
rized as failed revascularization underwent a reoper-
ation to restore patency in 100% of cases. Five failed
BGPs resulted in three embolectomies and two PTAs
of the BGP and were performed to achieve assisted
primary patency in the postoperative period. In
two patients the reoperation was not successful
and an amputation of the affected limb was needed
(one below-knee and one above-knee).
As listed in Table III, patients undergoing mini-
mally invasive revascularization procedures (PTA)
as well as open surgical procedures (BGP) had an
equal chance (total n¼ 34, 37%; PTA n¼ 13, 33%,
vs. BGP n¼ 21, 31%; p¼ 0.832) of experiencing
an AE. Also, no difference in the occurrence of the
total AEs (PTA n¼ 18, 30%, vs. BGP n¼ 30, 62%;
p¼ 0.757) was seen, stratified by types of primary
LEAR.
All systemic AEs resulted in irreversible physical
damage (n¼ 3, 27%) or, even worse, in the death
of the patient (n¼ 8, 73%). Causes of death
included arrhythmia (n¼ 1), cardiac arrest (n¼ 2),
myocardial infarction (n¼ 1), cardiogenic shock
(n¼ 2), hemorrhage (n¼ 1), and cerebrovascular
accident (n¼ 1) and resulted in a 30-day overall
mortality rate of 7.5%.DISCUSSION
The primary goal of this study was to assess the
occurrence of AEs after primary LEAR for CLI. The
secondary goal of the study was to evaluate the
impact of AEs on the clinical outcome of CLI
patients’ general health.
AEs are associated with poorer health outcomes
for patients and increase the average estimated total
costs in the treatment for PAOD.38 The registration
of AEs is a helpful tool to gain insight into the inci-
dence and type of AEs that might occur after revas-
cularization for CLI. It optimizes our awareness of all
unwanted developments in the illness of the
patients and in the treatment of illnesses that
occurred in the vascular department and their
(possibly preventable) causes. Furthermore, it gives
us the opportunity to evaluate the quality of the
work done and compare it with outcomes in the
literature. However, uniformity of these AE registra-
tion systems is necessary, to compare the results
between different health-care facilities.
Our results showed that 32% of the primary
revascularized CLI patients underwent 48 AEs in
Table II. Summary of Fontaine and TASC classifications and primary and secondary procedures of all
patients with primary CLI stratified by those with and without AEs
Characteristics Total Without AE With AE p
Fontaine classification30,31 0.257a
III 49 (46) 36 (50) 13 (38)
IV 57 (54) 36 (50) 21 (62)
TASC classification1,2
Femoral popliteal lesions 0.805a
Type B 39 (37) 26 (36) 13 (38)
Type C 16 (15) 12 (17) 4 (12)
Type D 51 (48) 34 (47) 17 (50)
Primary procedures 106 (82) 72 (100) 34 (60) 0.817a
PTA 39 (37) 26 (36) 13 (38) 0.345a
Femoral popliteal 67 (63) 46 (64) 21 (62)
Type B lesion 0.822a
BGP 16 (15) 12 (17) 4 (12)
Femoral popliteal SG 30 (28) 20 (28) 10 (29)
Femoral popliteal IG 21 (20) 14 (19) 7 (21)
Femoral crural
Secondary procedures 23 (18) 0 (0) 23 (40) 0.000b
Vascular 8 (35) 0 (0) 8 (35) 0.000b
RoBGP 5 (17) 0 (0) 5 (17)
RiBGP 1 (3) 0 (0) 1 (3)
Hemorrhage 2 (7) 0 (0) 2 (7)
Nonvascular 15 (65) 0 (0) 15 (65) 0.000b
Wound drainage 2 (7) 0 (0) 2 (7)
Skin grafting 2 (3) 0 (0) 2 (3)
Necrotectomy 3 (10) 0 (0) 3 (10)
Minor amputation 6 (20) 0 (0) 6 (20)
Major amputation 2 (7) 0 (0) 2 (7)
Patients withsecondary procedures 16 (15) 0 (0) 16 (47) 0.000a
Data are presented as n and percentages, unless otherwise specified. SG, supragenual; IG, infragenual; RoBGP, revascularization of
bypass graft; RiBGP, removal of infected bypass graft.
aChi-squared test.
bMann-Whitney U-test.
Table III. Summary of AEs of all patients with primary CLI: stratified by primary revascularization (PTA
vs. BGP)
Characteristics Total (n¼ 106) PTA (n¼ 39) BGP (n¼ 67) p
Cause
Minor other 8 (33) 5 (28) 3 (10) 0.247a
Surgical 16 (27) 7 (39) 9 (30) 0.338a
Systemic 15 (25) 6 (33) 9 (30) 0.738a
Failed revascularization 9 (15) 0 (0) 9 (30) 0.001a
Patients with AEs 34 (32) 13 (33) 21 (31) 0.832a
Total AEs 48 (100) 18 (38) 30 (62) 0.757a
Data are presented as n and percentages, unless otherwise specified.
aMann-Whitney U-test.
588 Flu et al. Annals of Vascular Surgerythe 30-day perioperative period. As outlined in
Tables III and IV, 31% of the AEs were systemic, of
which 47% were of cardiac cause. Cardiac AEs are
the leading cause of morbidity and mortality in
patients undergoing vascular surgery.39 Numerous
reports have also confirmed that patientsundergoing vascular reconstruction have an
increased risk of perioperative cardiac AEs.40-42 As
shown in Figure 1, profound impacts on patient
morbidity and mortality were observed after
systemic AEs; and these should be prevented during
the pre-, peri-, and postoperative periods. It is
Table IV. AEs (n¼ 48) after primary





Urinary tract infection 6 (13)
Deep venous thrombosis 1 (2)
Total 8 (17)
Surgical
Wound dehiscence 1 (2)





BGP infection 1 (2)




Respiratory failure 1 (2)
Arrhythmia 1 (2)
Cardiac arrest 2 (4)
Cardiogenic shock 3 (2)
Congestive heart 1 (2)
failure
Myocardial infarction 2 (4)
Stroke 3 (4)
Total 15 (31)
Total AEs 48 (100)
Data are presented as n and percentages, unless otherwise
specified.
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cardiac in 75% of the patients, resulting in a 30-
day overall mortality rate of 7.5% compared to up
to 3.9-8% mortality in the previous literature.43-50
There were no significant differences in risk
factors, comorbidity, BMI, and Fontaine classifica-
tion between patients with or without AEs. This
could be explained by the fact that CLI is accompa-
nied by extensive comorbid conditions in almost
all patients.
Detailed analysis of variables correlated with the
occurrence of AEs revealed that patients without
AEs were treated more often with b-blockers
compared to patient with AEs. Guidelines on perio-
perative care recommend that high-risk cardiac
patients should receive a b-blocker.3-5,51-55
However, available data also suggest that b-blockers
are underused in patients undergoing revasculariza-
tion,56-59 which was also the case with the CLI
patients suffering from cardiac AEs in this study.
According to the literature,51,60-66 the use ofb-blockers 1 or 2 weeks prior to surgery and
continuing beyond surgery is advised to achieve
adequate heart rate control, ultimately resulting in
a decrease of the incidence of perioperative cardio-
vascular AEs, and to offer long-term survival benefit.
Also, the withdrawal of b-blockers prior to major
surgery is associated with an increased incidence of
cardiovascular morbidity and mortality. Further-
more, detailed analysis revealed that patients with
antiplatelet agents experience fewer AEs compared
to patients without this medication. The use of anti-
platelet agents is indicated as secondary cardiovas-
cular prevention in patients presenting with
PAOD.60,67-69 A patient who has withdrawn antipla-
telet agents prior to the event has a worse outcome
than one who either continues on antiplatelet agents
or has never received this therapy.
No difference was seen in primary revasculariza-
tion (PTA vs. BGP) in all CLI patients stratified by the
occurrence of AEs. This indicates that the widely
accepted hypothesis that minimally invasive revas-
cularization procedures (PTA) are accompanied by
fewer AEs compared to BGP should not be accepted.
A possible explanation for the relatively high
percentage of AEs in the PTA group could be the
extensive comorbid status of the CLI patients with
their subsequent susceptibility for hemodynamic
imbalance after use of contrast agents. Another
explanation could be found in the fact that in this
study, in contrast to most AE studies, postdischarge
AEs in the outpatient clinic were also included.
In order to reduce AEs and thereby patient
morbidity and mortality, we suggest that the pre-,
intra-, and postoperative cardiac management
should be one of the main important goals during
endovascular and surgical treatment of these high-
risk CLI patients.Preoperative Multidisciplinary MeetingWhen considering a patient for revascularization,
a careful preoperative clinical risk evaluation
(Fig. 2) is essential. Extensive cardiac preoperative
assessment and optimization according to the
TASC and ACC/AHA guidelines is of utmost
importance to reduce perioperative cardiac AEs.
Second, as already stated, guidelines on periopera-
tive care recommend that high-risk cardiac patients
should receive a b-blocker.3-5,51-55 Third, blood
pressure-lowering therapy leads to reduction in
cardiovascular events in patients with PAOD.60,70-75
Fourth, the use of HMG-CoA reductase inhibitors
may reduce the risk of perioperative myocardial
infarction and the risk of major vascular events.
Cessation of HMG-CoA reductase inhibitors is
A. PHYSICAL STATUS
I. Characteristics 
• age (years) 
• gender 
II. Status of the extremity 
      • significant tissue loss of the weight-bearing areas of the foot
      • fixed and unremediable flexion contracture 
III. Minimal invasive tests 
      • blood pressure (mmHG) and heart rate (beats/min) 
DUE
Adequacy of the arterial system
      • ABI and resting AP
      • Outflow / runoff status (1-, 2 - or 3 arteries) 
Adequacy of the venous system (graft material) 
     • saphena magna vein,  saphena parva vein,  cephalic vein
B. LABORATORY STATUS
I.     Diabetse mellitus
       HbA1c  and glucose 
II. Coagulation and vicosity
       Trombocytes, aPTT, PT, INR, Hgb, Ht
III.    Renal 
        Urea, creatinine 
IV.   Electrolytes
        Potassium and sodium
V. Cardiac 
        Cardiac troponine T 
VI.   Hyperlipidaemia 
        Cholesterol, HDL, LDL 
VII.  Nutrition 
        Serum albumine
C. MEDICATION STATUS
I.  Home (check the presence of the medication used by the CLI patient)
     aspirin, clopidogrel, dipyridamole, warfarin, statin, digoxin, ACE-inhibitor, beta-blocker, calcium antagonist, angiotensin II     
     antagonist, diuretic, oral hypoglycaemic, insulin.
II. Secondary prevention (prescribe these medications to the PAOD patient)
     • β-blockers *achieve a resting heart rate between 65 - 70 beats/min the day before revascularization (bisoprolol 2,5 mg 
       once/day, 1 or 2 weeks prior to revascularization) 51, 60-66
     • ACE-inhibitors *treatment target non diabetic < 140/90 mmHG and diabetic/renal insufficiency < 130/80 mmHG 60, 70-75
     • HMG-CoA-reductase inhibitors *low-risk and intermediate risk LDL < 100mg/dL and high risk LDL < 70 mg/dL 60, 76-83
     • anti-platelet agents *aspirin in daily dosis of 75-325 mg or clopidogrel in daily dosis of 75 mg 60,67-69
D. RISK FACTORS AND COMORBIDITY STRATIFICATION
I. Cardiovascular (check the presence of the following risk factors/comorbidity of the PAOD patient)
• angina pectoris (stable, unstable, NYHA-classification) 4
     • myocardial infarction (< 1 year, > 1 year, NYHA-classification) 4
• arrhythmia  (NYHA-classification) 4
     • heart rate failure *mentioned earlier 
     • valvular disease 84
     • stroke or transient ischaemic attacks 
     • previous revascularization (PTCA, CABG, PTA, CEA)
II. Clinical (check the presence of the following risk factors/comorbidity of the PAOD patient)
     • BMI < 25 33
     • smoking (former, current, pack years)
• hypertension (WHO/ISH-classification) 85 *mentioned earlier
     • hyperlipidaemia (NCEP-classification) 86 *mentioned earlier 
• diabetes mellitus (controlled by diet/oral agents/insulin) *HbA1c < 7%, maximal blood glucose concentration in hospitalized patients not to 
exceed 180 mg per dL and in ICU patients should be controlled to less than 110 mg per dL 87, 88
     • renal insufficiency (NKF-DOQI-classification) 89
     • COPD (GOLD-classification) 90-92
E. PAST HISTORY
I. Vascular
    • Endovascular: PIER / PTA / stent 
    • Vascular: TE / EA / BGP => level of distal anastomosis, graft (autologous / PTFE / dacron)   
II. Non-vascular
    • Cutis/subcutis: necrotectomy / wound drainage
    • Ampuation: TMA / BKA / TKA / AKA
aPTT=activated partial thromboplastin time; PT=prothrombin time; NR=international normalized ratio; Hgb=haemoglobin;
Ht=haematocrit; LDL=low density lipoprotein; HDL=high density lipoprotein; ACE=angiotensin converting enzyme; NYHA= New 
York Heart Association; PTCA=percutaneous transluminal coronary angioplasty; CABG=coronary artery bypass grafting;
PTA=percutaneous transluminal angioplasty; CEA=carotid endarterectomy; EA=endarterectomy; BGP=bypass graft procedure;
BMI=body mass index;WHO/ISH=world health organization/ International Society of Hypertension; NCEP=national cholesterol 
education Program; ICU=intensive care unit; NKF-DOQI=national kidney foundation-disease outcomes quality initiative; 
COPD=chronic obstructive pulmonary disease; GOLD= global initiative on obstructive lung diseases.
Fig. 2. Preoperative multidisciplinary meeting; clinical risk
evaluation and subsequent risk-reduction strategies. aPTT,
activated partial thromboplastin time; PT, prothrombin
time; DUE, duplex ultrasound examination; ABI, ankle-
brachial index; AP, arterial pressure; INR, international
normalized ratio; Hgb, hemoglobin; Ht, hematocrit; LDL,
low-density lipoprotein; HDL, high-density lipoprotein;
ACE, angiotensin-converting enzyme; NYHA, New York
Heart Association; PTCA, percutaneous transluminal coro-
nary angioplasty; CABG, coronary artery bypass grafting;
PTA, percutaneous transluminal angioplasty; CEA, carotid
endarterectomy; EA, endarterectomy; BGP, bypass graft;
BMI, body mass index; WHO/ISH, World Health Organiza-
tion/International Society of Hypertension; NCEP, National
Cholesterol Education Program; ICU, intensive care unit;
NKF-DOQI, National Kidney Foundation-Disease
Outcomes Quality Initiative; COPD, chronic obstructive
pulmonary disease; GOLD, Global Initiative on Obstructive
Lung Diseases; TMA, transmetatarsal amputation; BKA,
below-knee amputation; TKA, through-knee amputation;
AKA, above-knee amputation; PIER, percutaneous inten-
tional extraluminal revascularization; TE, thromboembo-
lectomy; EA, endarterectomy.
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Every patient must be discussed in the pre-operative vascular meeting (B) and the clinical risk evaluation (C) 
B. VASCULAR MEETING 
PARTICIPANTS
Vascular surgeon 
• decision on type of treatment (LEAR or amputation)
Ultrasound technicians (DUE results)
• arterial evaluation occlusion or thrombosis, ABI
• adequacy of the venous system
Intervention radiologist (angiography results)
• arterial evaluation occlusion or thrombosis: TASC-lesion 
CONCLUSION : TYPE OF THERAPY
Urgency: elective / urgent < 2 hours / immediate 
Revascularization
• endovascular: PIER / PTA / stent 
• surgical: TE / EA / BGP => level of distal anastomosis, 
   graft (autologous / PTFE / dacron)
Major amputation: TMA / BKA / TKA / AKA
C. CLINICAL RISK EVALUATION (Figure III)
Vascular internal medicine / anaesthesiologist 
Physical status
• characteristics, minimal invasive tests 
Laboratory status
• DM, coagulation, renal, electrolytes, cardiac, HL, ECG 
Medication status
• home and secondary prevention
Risk factor and comorbidity stratification
• cardiovascular and / or clinical
Past history 
• vascular and / or non-vascular 
CONCLUSION: TYPE OF RISK REDUCTION STRATEGY
CARDIOLOGY PULMONARY MEDICINE VASCULAR INTERNAL MEDICINE NEPHROLOGY
D. INPATIENT ANAESTHESIOLOGY CLINIC
CONCLUSION: FORFILLED COMORBIDITY AND RISK MANAGEMENT
• cancel, delay (optimization comorbidity) or proceed with planned revascularization
• comorbidity and risk management at admission 24 hours pre-operative 
• post-operative care on surgical ward or ICU 
Only if indicated by the clinical risk evaluation, the patient must be optimized concerning individual comorbidity 
E. INTRA-OPERATIVE PATIENT SURVEILLANCE
Body temperature 
• prevent hypothermia (temperature < 35 C) and achieve an active pursuit of normothermia (core temperature  35 C) 93, 94
Cardiac monitoring
• monitoring ST-segment and cardiac troponine T 95-106
Blood glucose control 
• HbA1c < 7%, maximal blood glucose in hospitalized patients < 180 mg per dL and in ICU patients < 110 mg per dL 87, 88
F. POST-OPERATIVE PATIENT MANAGEMENT
Strategy mentioned above (E. INTRA-OPERATIVE PATIENT SURVEILLANCE) 
Blood pressure
• treatment target non diabetic < 140/90 mmHG and diabetic/renal insufficiency < 130/80 mmHG 60, 70-75, 107-111
Hart rate
• achieve a resting heart rate between 65 - 70 beats/min the day before revascularization (bisoprolol 2.5 mg once/day during the  
   post-operative period) 51, 60-66
Pain management
• an effective analgesic regimen, by epidural anaesthesia/analgesia, must be included 112-114
Anaemia 
• patients > 65 yrs, with a cardiac and/or respiratory disease and with a Hgb < 8g/dL should receive 2 units of packed RBC 115-121 
• stable patients with Hgb < 6g/dL should receive 2 units of packed RBC 115-121
Coagulability and viscosity 
• transfusion of FFP is indicated if PT, INR, and aPTT are not normal 121
TASC & AHA/ACC 1-5 AIM & ACCP 90-92 TASC & AHA/ACC 1-5 NKF-DOQI 89
A. ULTIMATE GOALS OF CLI TREATMENT 
(1) Diminish the occurrence of EAs (total and / or systemic) in the postoperative period. (2) Diminish the occurrence of secondary 
procedures in the postoperative period. (3) Graft patency resulting in an absolute decrease of rest pain and / or leading to the point
of wound healing. (4) Maintenance of ambulatory status and living situation. (5) Limb salvage. (6) Patient survival. 
PIER=Percutaneous intentional extraluminal revascularization; PTA=percutaneous transluminal angioplasty;
TE=thromboembolectomy; EA=endarterectomy; BGP=bypass graft procedure; PTFE=polytetrafluoroethylene;
TMA=transmetatarsal amputation; BKA=below knee amputation; TKA=through knee amputation; AKA=above knee amputation; 
DM=diabetes mellitus; HL=hyperlipidaemia; ECG=electrocardiogram; TASC=Trans Atlantic Inter-Society Consensus;
AHA/ACC= the American College of Cardiology and the American Heart Association; AIM=annals of internal medicine clinical
guidelines; ACCP= American College of Chest Physicians; NKF-DOQI=national kidney foundation-disease outcomes quality
initiative; ICU=intensive care unit; Hgb=haemoglobin; RBC=red blood cells; FFP=fresh frozen plasma; aPTT=activated partial
thromboplastin time; PT=prothrombin time; INR=international normalized ratio.
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compared to patients who continue their therapy
or those who have never been on a HMG-CoA
reductase inhibitor.60,76-83 Fifth, the use of antipla-
telet agents is indicated as secondary cardiovascular
prevention in patients presenting with PAOD.Intraoperative Patient SurveillanceThe intraoperative patient surveillance is shown in
Figure 3. First, prevent intraoperative hypothermia
and myocardial ischemic burden; they are indepen-
dent predictors of perioperative morbid cardiac
AEs.93-98 Intraoperative and postoperative ST-
segment monitoring and troponin T release can be
useful to monitor patients with single or multiple
risk factors for coronary artery disease, with known
coronary artery disease, or undergoing vascular
surgery.97-106 Second, hyperglycemia is an indepen-
dent predictor of cardiovascular risk; the severity of
hyperglycemia is directly related to mortality rate
during myocardial ischemia.107-111 Blood glucose
concentration should be controlled during the peri-
operative period in patients with diabetes mellitus
or acute hyperglycemia who are at high risk for
myocardial ischemia when undergoing major revas-
cularization procedures.96,97Postoperative Patient ManagementThe postoperative patient management is shown in
Figure 3. Because the majority of cardiac events in
noncardiac surgical patients occur postoperatively,
the postoperative period may be the time during
which ablation of stress, adverse hemodynamics,
and hypercoagulable responses are most critical.
Epidural anesthesia/analgesia result in lower opiate
dosages, a better ablation of the catecholamine res-
ponse, and a reduction of hypercoagulability.
112-114 Second, anemia and hematocrit <28-30%
impose stress on the cardiovascular system that
may exacerbate myocardial ischemia and aggravate
heart failure.115-121 Third, hyperviscosity andFig. 3. Flowchart of preoperative multidisciplinary
vascular meeting and clinical risk evaluation, intraopera-
tive patient surveillance, and postoperative patient
management. ABI, ankle-brachial index; LEAR, lower
extremity arterial revascularization; PIER, percutaneous
intentional extraluminal revascularization; PTA, per-
cutaneous transluminal angioplasty; TE, thromboembo-
lectomy; EA, endarterectomy; BGP, bypass graft
procedure; PTFE, polytetrafluoroethylene; TMA, trans-
metatarsal amputation; BKA, below-knee amputation;
TKA, through-knee amputation; AKA, above-kneehypercoagulability have also proven to be markers
of poor prognosis.1-5,121LimitationsBecause of its retrospective nature, our study has
limitations, which should be considered when inter-
preting the results. The number of patients in the
present study does not permit further analyses in
depth. Patients with previous surgical treatment
for CLI were excluded in this study to reduce the
influence of previous AEs on the outcome of the
current treatment. The sample was composed exclu-
sively of patients with CLI, and our results may not
generalize to other patient samples. It should be
appreciated that our results were obtained in one
high-volume hospital and that cardiac event rates
might differ in other centers.CONCLUSION
AEs occur in >30% of CLI patients after LEAR. The
most harmful AEs on the clinical outcome of CLI
patients were heart-related, causing increased
morbidity and death. Significant correlations
between prescription of b-blockers and/or antiplate-
let agents and prevention of AEs were observed.
A persistent focus on the prevention of systemic
AEs in order to ameliorate the outcome after LEAR
for limb salvage remains of utmost importance.
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Appendix 1. Classification of AEs and
explanation of causes
Categorya




Cardiac 1 Minor I No consequence















aThese categories were further subdivided as listed in Appendix
II.
bExplanation and definition of the causes of perioperative
complications: minor, an AE such as urinary tract infection or
deep venous thrombosis; surgical, an AE due to surgical treat-
ment, such as abscess, wound infection, wound necrosis, wound
dehiscence, hemorrhage; failed revascularization, when a primary
bypass graft occluded or at risk for occlusion and surgical or
endovascular reintervention was performed or when an
anatomical arterial segment occluded after a PTA was performed
on that same segment; systemic, potential life-threatening AEs,
such as pneumonia, respiratory failure, arrhythmia, cardiac
arrest, cardiogenic shock, congestive heart failure, myocardial
infarction, shock, stroke.




























































Error in medication, diagnosis, judgment, or technique
Delay to OR, in MD response, or in diagnosis
Incomplete hospital record
BGP¼ bypass graft procedure; PTA¼ percutaneous transluminal
angioplasty; OR¼ operating room; MD¼medical doctor.
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